I’m so tired of seeing articles announcing a new migraine drug is in development, then discovering it’s an old drug with a different delivery system. These are not new drugs, even though press releases pretend that they are.
The investigation and marketing of these new routes will help patients. Gastric stasis and vomiting can impair the efficacy of a swallowed medication, so being able to bypass these complications is beneficial. Some people who have never gotten relief from a triptan before may find that they suddenly work when taking as an injection, nasal spray, patch or oral film. These are important points, but they don’t add up to something being a new drug.
If new migraine abortives were also being developed and reported, the investigation into new delivery routes for old drugs probably would not bother me. The problem is that I so desperately want new migraine drugs to be in development that these announcements always raise my hopes.
I know better, I really do. And knowing that — what the migraine research landscape looks like — may be the bleakest part of it all.